Key result
Endogenous methylarginines, specifically L-NMMA and ADMA, accumulate in various diseases and act as endogenous inhibitors of nitric oxide synthase, contributing to impaired nitric oxide production.
Endogenous methylarginines such as ADMA and L-NMMA act as critical inhibitors of nitric oxide synthase, and their accumulation plays a key pathophysiological role in endothelial dysfunction and cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
Should not yet alter clinical practice; leaves open therapeutic targeting of methylarginines in endothelial dysfunction.
Protein arginine N-methyltransferases (PRMTs) catalyse the methylation of guanidinonitrogen(s) of arginine to produce NG-monomethyl-L-arginine (L-NMMA), asymmetric NG,NG-dimethyl-L-arginine (ADMA) and symmetric NG,NG-dimethyl-L-arginine (SDMA), which are subsequently released into the cytoplasm following proteolysis. Free intracellular L-NMMA and ADMA, but not SDMA, are inhibitors of all three isoforms of nitric oxide synthases (nNOS, eNOS and iNOS). L-NMMA and ADMA, but not SDMA, are actively metabolized by dimethylarginine dimethylaminohydrolase (DDAH) to L-citrulline and methylamine (and dimethylamine). Free methylarginines are detectable in cell cytosol, plasma and tissues. Elevated ADMA has been detected in the plasma of patients or experimental animals with hypercholesterolemia, renal failure, atherosclerosis, hypertension, thrombotic microangiopathy, peripheral arterial occlusive disease and in the regenerated endothelial cells after angioplasty. Moreover, in the non-cardiovascular field, ADMA was increased in the urethral tissue following ischemia and in the plasma of patients with schizophrenia and multiple sclerosis. Altered biosynthesis of NO has been implicated in the pathogenesis of these diseases, and it is possible to consider that the accumulation of endogenous L-NMMA and ADMA underlies the impaired NO generation and increased O2- production. We described herein the biosynthesis, transmembrane transport, metabolic pathway and possible pathophysiological roles of endogenous methylarginines.
No takes yet. Share an insight, caveat, or question.
Masuda et al. (2002) conducted a review in Diseases associated with impaired nitric oxide production. Endogenous methylarginines (L-NMMA, ADMA) was evaluated. Endogenous methylarginines, specifically L-NMMA and ADMA, accumulate in various diseases and act as endogenous inhibitors of nitric oxide synthase, contributing to impaired nitric oxide production.
Synapse has enriched 10 related papers. Consider them for comparative context: